Previous studies investigating the mechanism of the transcriptional regulation of POLE expression and mutations in carcinogenesis show that POLE or POLD1 mutations serve as negative prognostic markers and may predict a survival benefit from ICI therapy across diverse cancers (Wang et al., 2019b). The gene discussed is POLE; the disease is cancer.